Renal function and symptoms/adverse effects in opioid-treated patients with cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Renal function and symptoms/adverse effects in opioid-treated patients with cancer. / Kurita, G P; Lundström, S; Sjøgren, P; Ekholm, O; Christrup, L; Davies, A; Kaasa, S; Klepstad, P; Dale, O.

In: Acta Anaesthesiologica Scandinavica, Vol. 59, No. 8, 09.2015, p. 1049-59.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kurita, GP, Lundström, S, Sjøgren, P, Ekholm, O, Christrup, L, Davies, A, Kaasa, S, Klepstad, P & Dale, O 2015, 'Renal function and symptoms/adverse effects in opioid-treated patients with cancer', Acta Anaesthesiologica Scandinavica, vol. 59, no. 8, pp. 1049-59. https://doi.org/10.1111/aas.12521

APA

Kurita, G. P., Lundström, S., Sjøgren, P., Ekholm, O., Christrup, L., Davies, A., Kaasa, S., Klepstad, P., & Dale, O. (2015). Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta Anaesthesiologica Scandinavica, 59(8), 1049-59. https://doi.org/10.1111/aas.12521

Vancouver

Kurita GP, Lundström S, Sjøgren P, Ekholm O, Christrup L, Davies A et al. Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta Anaesthesiologica Scandinavica. 2015 Sep;59(8):1049-59. https://doi.org/10.1111/aas.12521

Author

Kurita, G P ; Lundström, S ; Sjøgren, P ; Ekholm, O ; Christrup, L ; Davies, A ; Kaasa, S ; Klepstad, P ; Dale, O. / Renal function and symptoms/adverse effects in opioid-treated patients with cancer. In: Acta Anaesthesiologica Scandinavica. 2015 ; Vol. 59, No. 8. pp. 1049-59.

Bibtex

@article{6f6cb4c5961946088ec6554b3fc25a29,

title = "Renal function and symptoms/adverse effects in opioid-treated patients with cancer",

abstract = "BACKGROUND: Renal impairment and the risk of toxicity caused by accumulation of opioids and/or active metabolites is an under-investigated issue. This study aimed at analysing if symptoms/adverse effects in opioid-treated patients with cancer were associated with renal function.METHODS: Cross-sectional multicentre study (European Pharmacogenetic Opioid Study, 2005-2008), in which 1147 adult patients treated exclusively with only one of the most frequently reported opioids (morphine/oxycodone/fentanyl) for at least 3 days were analysed. Fatigue, nausea/vomiting, pain, loss of appetite, constipation and cognitive dysfunction were assessed (EORTC QLQ-C30). Glomerular filtration rate (GFR) was estimated using Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI Creatinine) equations.RESULTS: Mild to severe low GFR was observed among 40-54% of patients. CG equation showed that patients with mild and moderate/severe low GFR on morphine treatment had higher odds of having severe constipation (P < 0.01) than patients with normal GFR. In addition, patients with moderate/severe low GFR on morphine treatment were more likely to have loss of appetite (P = 0.04). No other significant associations were found.CONCLUSION: Only severe constipation and loss of appetite were associated with low GFR in patients treated with morphine. Oxycodone and fentanyl, in relation to the symptoms studied, seem to be safe as used and titrated in routine cancer pain care.",

author = "Kurita, {G P} and S Lundstr{\"o}m and P Sj{\o}gren and O Ekholm and L Christrup and A Davies and S Kaasa and P Klepstad and O Dale",

note = "{\textcopyright} 2015 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.",

year = "2015",

month = sep,

doi = "10.1111/aas.12521",

language = "English",

volume = "59",

pages = "1049--59",

journal = "Acta Anaesthesiologica Scandinavica",

issn = "0001-5172",

publisher = "Wiley-Blackwell",

number = "8",

}

RIS

TY - JOUR

T1 - Renal function and symptoms/adverse effects in opioid-treated patients with cancer

AU - Kurita, G P

AU - Lundström, S

AU - Sjøgren, P

AU - Ekholm, O

AU - Christrup, L

AU - Davies, A

AU - Kaasa, S

AU - Klepstad, P

AU - Dale, O

PY - 2015/9

Y1 - 2015/9

N2 - BACKGROUND: Renal impairment and the risk of toxicity caused by accumulation of opioids and/or active metabolites is an under-investigated issue. This study aimed at analysing if symptoms/adverse effects in opioid-treated patients with cancer were associated with renal function.METHODS: Cross-sectional multicentre study (European Pharmacogenetic Opioid Study, 2005-2008), in which 1147 adult patients treated exclusively with only one of the most frequently reported opioids (morphine/oxycodone/fentanyl) for at least 3 days were analysed. Fatigue, nausea/vomiting, pain, loss of appetite, constipation and cognitive dysfunction were assessed (EORTC QLQ-C30). Glomerular filtration rate (GFR) was estimated using Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI Creatinine) equations.RESULTS: Mild to severe low GFR was observed among 40-54% of patients. CG equation showed that patients with mild and moderate/severe low GFR on morphine treatment had higher odds of having severe constipation (P < 0.01) than patients with normal GFR. In addition, patients with moderate/severe low GFR on morphine treatment were more likely to have loss of appetite (P = 0.04). No other significant associations were found.CONCLUSION: Only severe constipation and loss of appetite were associated with low GFR in patients treated with morphine. Oxycodone and fentanyl, in relation to the symptoms studied, seem to be safe as used and titrated in routine cancer pain care.

AB - BACKGROUND: Renal impairment and the risk of toxicity caused by accumulation of opioids and/or active metabolites is an under-investigated issue. This study aimed at analysing if symptoms/adverse effects in opioid-treated patients with cancer were associated with renal function.METHODS: Cross-sectional multicentre study (European Pharmacogenetic Opioid Study, 2005-2008), in which 1147 adult patients treated exclusively with only one of the most frequently reported opioids (morphine/oxycodone/fentanyl) for at least 3 days were analysed. Fatigue, nausea/vomiting, pain, loss of appetite, constipation and cognitive dysfunction were assessed (EORTC QLQ-C30). Glomerular filtration rate (GFR) was estimated using Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI Creatinine) equations.RESULTS: Mild to severe low GFR was observed among 40-54% of patients. CG equation showed that patients with mild and moderate/severe low GFR on morphine treatment had higher odds of having severe constipation (P < 0.01) than patients with normal GFR. In addition, patients with moderate/severe low GFR on morphine treatment were more likely to have loss of appetite (P = 0.04). No other significant associations were found.CONCLUSION: Only severe constipation and loss of appetite were associated with low GFR in patients treated with morphine. Oxycodone and fentanyl, in relation to the symptoms studied, seem to be safe as used and titrated in routine cancer pain care.

U2 - 10.1111/aas.12521

DO - 10.1111/aas.12521

M3 - Journal article

C2 - 25943005

VL - 59

SP - 1049

EP - 1059

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 8

ER -

ID: 161864714